NRF2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells

Toxicology and Applied Pharmacology

Volumn 267, Issue 1, 2013, Pages 30-40

  Pecorelli, Alessandra ^a,b   Bocci, Velio ^a   Acquaviva, Alessandra ^a   Belmonte, Giuseppe ^a   Gardi, Concetta ^a   Virgili, Fabio ^c   Ciccoli, Lucia ^a   Valacchi, Giuseppe ^d,e  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c ISTITUTO NAZIONALE DELLA NUTRIZIONE   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e Kyung Hee University   (South Korea)

Author keywords

4 hydroxynonenal; Heme oxygenase 1; Hydrogen peroxyde; Keap1; Ozone

Indexed keywords

4 HYDROXYNONENAL; ELECTROPHILE; HEME OXYGENASE 1; HYDROGEN PEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NADPH QUINONE OXIDOREDUCTASE; OZONE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; AUTOHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; ELECTROPHILE RESPONSIVE ELEMENT; ENDOTHELIUM CELL; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; OZONATION; PROTEIN BINDING; PROTEIN SYNTHESIS; UPREGULATION;

CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HEME OXYGENASE-1; HOMEOSTASIS; HUMANS; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; OZONE; SERUM; UP-REGULATION;

EID: 84872285528     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.12.001     Document Type: Article

References (51)

1. Adibhatla R.M., Hatcher J.F. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 2010, 12:125-169.
2. Barber E., Menéndez S., León O.S., Barber M.O., Merino N., Calunga J.L., Cruz E., Bocci V. Prevention of renal injury after induction of ozone tolerance in rats submitted to warm ischaemia. Mediators Inflamm. 1999, 8:37-41.
3. Biedunkiewicz B., Tylicki L., Nieweglowski T., Burakowski S., Rutkowski B. Clinical efficacy of ozonated autohemotherapy in hemodialyzed patients with intermittent claudication: an oxygen-controlled study. Int. J. Artif. Organs 2004, 27:29-34.
4. Bocci V. Ozone as a bioregulator. Pharmacology and toxicology of ozonetherapy today. J. Biol. Regul. Homeost. Agents 1996, 10:31-53.
5. Bocci V. Is it true that ozone is always toxic? The end of a dogma. Toxicol. Appl. Pharmacol. 2006, 216:493-504.
6. Bocci V. Retinal degenerative disorders. Ozone. A new medical drug 2011, 133-145. Springer, Dordrecht, The Netherlands. 2nd edition.
7. Bocci V. How a calculated oxidative stress can yield multiple therapeutic effects. Free Radic. Res. 2012, 46:1068-1075.
8. Bocci V., Valacchi G., Corradeschi F., Aldinucci C., Silvestri S., Paccagnini E., Gerli R. Studies on the biological effects of ozone: 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone. J. Biol. Regul. Homeost. Agents 1998, 12:67-75.
9. Bocci V., Valacchi G., Corradeschi F., Fanetti G. Studies on the biological effects of ozone: 8. Effects on the total antioxidant status and on interleukin-8 production. Mediators Inflamm. 1998, 7:313-317.
10. Bocci V., Aldinucci C., Mosci F., Carraro F., Valacchi G. Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm. 2007, 2007:26785-26790.
11. Bocci V., Borrelli E., Travagli V., Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med. Res. Rev. 2009, 29:646-682.
12. Calabrese V., Cornelius C., Cuzzocrea S., Iavicoli I., Rizzarelli E., Calabrese E.J. Hormesis, cellular stress response and vitagenes as critical determinants in aging and longevity. Mol. Aspects Med. 2011, 32:279-304.
13. Clavo B., Pérez J.L., López L., Suárez G., Lloret M., Rodríguez V., Macías D., Santana M., Morera J., Fiuza D., Robaina F., Günderoth M. Effect of ozone therapy on muscle oxygenation. J. Altern. Complement. Med. 2003, 9:251-256.
14. De Monte A., Gori C. Major ozonated autohaemotherapy in the treatment of limb ulcers not responding to conventional therapy. IJOT 2011, 10:85-98.
15. Di Paolo N., Bocci V., Cappelletti F., Petrini G., Gaggiotti E. Necrotizing fasciitis successfully treated with extracorporeal blood oxygenation and ozonization (EBOO). Int. J. Artif. Organs 2002, 25:1194-1198.
16. Di Paolo N., Bocci V., Gaggiotti E. Ozone therapy. Int. J. Artif. Organs 2004, 27:168-175.
17. Di Paolo N., Bocci V., Salvo D.P., Palasciano G., Biagioli M., Meini S., Galli F., Ciari I., Maccari F., Cappelletti F., Di Paolo M., Gaggiotti E. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. Int. J. Artif. Organs 2005, 28:1039-1050.
18. 2 involves KEAP1 disulfide formation. J. Biol. Chem. 2010, 285:8463-8471.
19. Grosser N., Abate A., Oberle S., Vreman H.J., Dennery P.A., Becker J.C., Pohle T., Seidman D.S., Schröder H. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem. Biophys. Res. Commun. 2003, 308:956-960.
20. Grosser N., Erdmann K., Hemmerle A., Berndt G., Hinkelmann U., Smith G., Schröder H. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem. Biophys. Res. Commun. 2004, 325:871-876.
21. Halliwell B. The antioxidant paradox. Lancet 2000, 355:1179-1180.
22. He M., Siow R.C., Sugden D., Gao L., Cheng X., Mann G.E. Induction of HO-1 and redox signaling in endothelial cells by advanced glycation end products: a role for Nrf2 in vascular protection in diabetes. Nutr. Metab. Cardiovasc. Dis. 2011, 21:277-285.
23. Iles K.E., Liu R.M. Mechanisms of glutamate cysteine ligase (GCL) induction by 4-hydroxynonenal. Free Radic. Biol. Med. 2005, 38:547-556.
24. Iles K.E., Dickinson D.A., Wigley A.F., Welty N.E., Blank V., Forman H.J. HNE increases HO-1 through activation of the ERK pathway in pulmonary epithelial cells. Free Radic. Biol. Med. 2005, 39:355-364.
25. Kang M.I., Kobayashi A., Wakabayashi N., Kim S.G., Yamamoto M. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proc. Natl. Acad. Sci. 2004, 101:2046-2051.
26. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89-116.
27. Kim A.N., Jeon W.K., Lee J.J., Kim B.C. Up-regulation of heme oxygenase-1 expression through CaMKII-ERK1/2-Nrf2 signaling mediates the anti-inflammatory effect of bisdemethoxycurcumin in LPS-stimulated macrophages. Free Radic. Biol. Med. 2010, 49:323-331.
28. Kim J., Cha Y.N., Surh Y.J. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat. Res. 2010, 690:12-23.
29. Lee T.S., Chang C.C., Zhu Y., Shyy J.Y. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 2004, 110:1296-1302.
30. León O.S., Menéndez S., Merino N., Castillo R., Sam S., Pérez L., Cruz E., Bocci V. Ozone oxidative preconditioning: a protection against cellular damage by free radicals. Mediators Inflamm. 1998, 7:289-294.
31. Leonarduzzi G., Robbesyn F., Poli G. Signaling kinases modulated by 4-hydroxynonenal. Free Radic. Biol. Med. 2004, 37:1694-1702.
32. Maheshwari R.K., Singh A.K., Gaddipati J., Srimal R.C. Multiple biological activities of curcumin: a short review. Life Sci. 2006, 78:2081-2087.
33. Minelli A., Conte C., Grottelli S., Bellezza M., Cacciatore I., Bolaños J.P. Cyclo(His-Pro) promotes cytoprotection by activating Nrf2-mediated up-regulation of antioxidant defence. J. Cell. Mol. Med. 2009, 13:1149-1161.
34. Motohashi H., Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 2004, 10:549-557.
35. Peralta C., León O.S., Xaus C., Prats N., Jalil E.C., Planell E.S., Puig-Parellada P., Gelpí E., Roselló-Catafau J. Protective effect of ozone treatment on the injury associated with hepatic ischemia-reperfusion: antioxidant-prooxidant balance. Free Radic. Res. 1999, 31:191-196.
36. Petersen D.R., Doorn J.A. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic. Biol. Med. 2004, 37:937-945.
37. Pryor W.A. Mechanisms of radical formation from reactions of ozone with target molecules in the lung. Free Radic. Biol. Med. 1994, 17:451-465.
38. Rokitanski O., Rokitanski A., Steiner J., Trubel W., Viebahn R., Washüttl J. Die ozontherapie bei peripheren, arteriellen Durchblutungs-strörugen; klinik, biochemische und blutgasanalytische untersuchungen. Wasser IOA 1981, 53-75. Ozon-Weltkongress, Berlin.
39. Sticozzi C., Belmonte G., Pecorelli A., Arezzini B., Gardi C., Maioli E., Miracco C., Toscano M., Forman H.J., Valacchi G. Cigarette smoke affects keratinocytes SRB1 expression and localization via H2O2 production and HNE protein adducts formation. PLoS One 2012, 7:e33592.
40. Stone J.R., Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium 2002, 9:231-238.
41. Stone J.R., Yang S. Hydrogen peroxide: A signaling messenger. Antioxid. Redox Signal. 2006, 8:243-270.
42. Sun Z., Zhang S., Chan J.Y., Zhang D.D. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol. Cell. Biol. 2007, 27:6334-6349.
43. Sun Z., Huang Z., Zhang D.D. Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. PLoS One 2009, 4:e6588.
44. Taguchi K., Motohashi H., Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011, 16:123-140.
45. Tylicki L., Nieweglowski T., Biedunkiewicz B., Chamienia A., Debska-Slizien A., Aleksandrowicz E., Lysiak-Szydlowska W., Rutkowski B. The influence of ozonated autohemotherapy on oxidative stress in hemodialyzed patients with atherosclerotic ischemia of lower limbs. Int. J. Artif. Organs 2003, 26:297-303.
46. Um H.C., Jang J.H., Kim D.H., Lee C., Surh Y.J. Nitric oxide activates Nrf2 through S-nitrosylation of Keap1 in PC12 cells. Nitric Oxide 2011, 25:161-168.
47. Valacchi G., Pecorelli A., Mencarelli M., Carbotti P., Fortino V., Muscettola M., Maioli E. Rottlerin: a multifaced regulator of keratinocyte cell cycle. Exp. Dermatol. 2009, 18:516-521.
48. Velichkova M., Hasson T. Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol. Cell. Biol. 2005, 25:4501-4513.
49. Yamamoto T., Suzuki T., Kobayashi A., Wakabayashi J., Maher J., Motohashi H., Yamamoto M. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol. Cell. Biol. 2008, 28:2758-2770.
50. Yang Y.C., Lii C.K., Lin A.H., Yeh Y.W., Yao H.T., Li C.C., Liu K.L., Chen H.W. Induction of glutathione synthesis and heme oxygenase 1 by the flavonoids butein and phloretin is mediated through the ERK/Nrf2 pathway and protects against oxidative stress. Free Radic. Biol. Med. 2011, 51:2073-2081.
51. Zhang D.D. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev. 2006, 38:769-789.